ClinConnect ClinConnect Logo
Search / Trial NCT01989975

CareLink Connect - Technical Evaluation Study

Launched by MEDTRONIC DIABETES · Nov 15, 2013

Trial Information

Current as of May 28, 2025

Completed

Keywords

Sensor Augmented Pump Therapy Connected Care

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Subject between the age of 12 - 65 years that has a clinical diagnosis of insulin requiring diabetes for at least 1 year
  • 2. Subject is currently using a Paradigm® Veo™ Medtronic insulin pump for at least 3 months and willing to continue to use for the duration of the study.
  • 3. Subject has sufficient Continuous Glucose Monitoring use experience, as determined by the Investigator, and is willing to continuously use CGM for the duration of the study.
  • Guidelines to evaluate the patients experience are:
  • i. Subject has a minimum of 30 days of CGM use within a year prior to enrollment.
  • ii. Subject has experience with and is able to, or has a Care Partner who can:
  • 1. Insert/change sensor,
  • 2. Recharge the transmitter.
  • 3. Read sensor data in real-time on the insulin pump screen.
  • 4. Subject is willing to, or has a Care Partner who can, perform at least the minimum required (2 per day) Blood Glucose readings to maintain CGM Sensor calibration.
  • 5. Subject, if under the age of 18, has a Care Partner who is willing to participate to the study, attend the study visit with the subject, and complete user's feedback questionnaires and Care Partner diary. Care Partners are optional for patients of 18 years of age or older.
  • 6. Subject and/or Care Partner have access to a computer with Internet access.
  • 7. Subject and/or Care Partner have access to an Internet connected device.
  • 8. Subject, or their legal guardian, is willing to allow a Care Partner to receive and view information transmitted by their Paradigm® Veo™ Medtronic insulin pump to a Mobile phone/Smartphone/tablet/PC via the CareLink Connect/CareLink Personal System.
  • 9. Subject is willing to keep CareLink Connect device in the same room as themselves or regularly carry the study device with them and maintain its operational status (at approximately 16h per 24h).
  • 10. Subject is willing to keep a short diary during the device use reporting time periods away(for more than one hour) from the CareLink Connect device.
  • 11. Subject is in good general health as judged by the PI.
  • Exclusion Criteria:
  • 1. Female subject is pregnant, per urine pregnancy test performed at screening in women of child-bearing potential
  • 2. Female subject plans to become pregnant during the course of the study
  • 3. Subject is unable to tolerate tape adhesives of the infusion set and CGM sensor
  • 4. Subject has any unresolved adverse skin condition in the area of the pump infusion set or the CGM sensor placement (e.g. psoriasis, rash, Staphylococcus infection)
  • 5. The subject has known cellular connectivity problem at their home
  • 6. The subject is by the PI judged ineligible or unable to perform the study procedures jeopardizing the study results.

About Medtronic Diabetes

Medtronic Diabetes is a leading global healthcare technology company dedicated to transforming diabetes management through innovative solutions and therapies. As a subsidiary of Medtronic plc, the organization focuses on developing advanced diabetes management systems, including insulin pumps, continuous glucose monitoring devices, and integrated software solutions. Committed to improving patient outcomes and enhancing quality of life, Medtronic Diabetes actively engages in clinical trials to evaluate the safety and efficacy of its products, contributing to the advancement of diabetes care and fostering collaboration with healthcare professionals and patients alike.

Locations

Gentofte, , Denmark

Rotterdam, , Netherlands

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials